Valuation: AC Immune SA

Capitalization 221M 284M 241M 208M 388M 26.79B 392M 2.62B 1.02B 12.87B 1.06B 1.04B 44.43B P/E ratio 2026 *
-6.6x
P/E ratio 2027 * 10.8x
Enterprise value 189M 243M 207M 179M 333M 22.99B 336M 2.25B 875M 11.04B 913M 894M 38.13B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 2.79x
Free-Float
56.1%
Yield 2026 *
-
Yield 2027 * -
1 day-2.05%
1 week-4.03%
Current month-5.61%
1 month-15.88%
3 months-8.04%
6 months-13.33%
Current year-8.92%
1 week 2.8
Extreme 2.8
3.16
1 month 2.8
Extreme 2.8
3.4
Current year 2.44
Extreme 2.44
3.9
1 year 1.51
Extreme 1.51
4
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
12.61
10 years 1.43
Extreme 1.4299
19.97
Manager TitleAgeSince
Chief Executive Officer 68 2003-02-12
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 68 2015-12-31
Director/Board Member 70 2018-12-31
Director/Board Member 72 2020-11-19
Change 5d. change 1-year change 3-years change Capi.($)
-2.05%-4.03%+70.24%+36.19% 284M
+0.82%+1.92%+35.45%-5.30% 72.73B
+0.56%+1.25%+51.67%+176.91% 52.45B
+0.27%+47.20%+47.20%+47.20% 46.63B
-1.74%-3.97%-49.91%-60.02% 42.13B
+1.08%+3.42%+63.70%-38.39% 28.56B
+11.97%+19.79%+124.12%-59.37% 21.57B
-1.21%0.00%+71.76%+131.66% 19.95B
+0.81%+1.70%+67.11%+52.17% 19.69B
-2.03%+1.73%+45.16%+67.00% 16.32B
Average +0.85%+2.19%+52.65%+34.81% 32.03B
Weighted average by Cap. +0.86%+1.97%+41.81%+34.18%

Financials

2026 *2027 *
Net sales 31.22M 40.15M 34.11M 29.46M 54.96M 3.79B 55.44M 370M 144M 1.82B 151M 147M 6.29B 90.43M 116M 98.81M 85.35M 159M 10.98B 161M 1.07B 418M 5.28B 436M 427M 18.22B
Net income -34.35M -44.18M -37.53M -32.42M -60.48M -4.17B -61.01M -407M -159M -2B -166M -162M -6.92B 19.44M 25M 21.24M 18.35M 34.22M 2.36B 34.53M 231M 89.89M 1.13B 93.8M 91.82M 3.92B
Net Debt -31.3M -40.26M -34.2M -29.54M -55.11M -3.8B -55.59M -371M -145M -1.83B -151M -148M -6.3B 32.1M 41.28M 35.08M 30.3M 56.52M 3.9B 57.01M 381M 148M 1.87B 155M 152M 6.47B
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
26-05-08 2.860 $ -2.05% 342,791
26-05-07 2.920 $ -1.68% 201,015
26-05-06 2.970 $ -1.33% 345,676
26-05-05 3.010 $ -1.31% 251,565
26-05-04 3.050 $ +2.35% 216,655
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.224CHF
Average target price
7.030CHF
Spread / Average Target
+216.13%

Quarterly revenue - Rate of surprise